If you purchased Trevena, Inc. (TRVN) and wish to serve as lead plaintiff in this securities class action, you must move the Court no later than December 10, 2018.
According to the complaint against the company's officers and directors for alleged violations of the Securities Exchange Act of 1934 between May 2, 2016 and October 9, 2018, Trevena led investors to believe that a critical meeting in April 2016 with the U.S. Food and Drug Administration ("FDA") was more successful than it actually was. The FDA revealed in October 2018 that it did not agree with the proposed dosing in Trevena's Phase 3 studies and subsequently denied Trevena's New Drug Application for oliceridine. Trevena's stock plummeted on this news and now trades under $1.00
Trevena, Inc. (TRVN) Shareholders Have Legal Options
Concerned shareholders who would like more information about their rights and potential remedies can please send us a message via the Shareholder Information form below.